Liu, Jun
Hong, Junshik
Han, Heejoo
Park, Jihyun
Kim, Dongchan
Park, Hyejoo
Ko, Myunggon
Koh, Youngil
Shin, Dong-Yeop
Yoon, Sung-Soo
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2018R1C1B5085214)
Article History
Received: 9 June 2019
Revised: 5 February 2020
Accepted: 26 February 2020
First Online: 16 March 2020
Ethics approval and consent to participate
: The use of the patient-derived primary AML cells from seven patients was reviewed and approved by the Institutional Review Board of the Seoul National University Hospital (Approval number: H-1905-133-1035). Informed consent was obtained from all seven patients. This study was conducted in accordance with the Declaration of Helsinki.
: No consent was required for this publication.
: All data and materials generated and/or analysed during the current study are available from the corresponding author upon reasonable request.
: The authors declare no competing interests.
: This work was supported by the National Research Foundation of Korea (NRF) (grant funded by the Korean government Ministry of Science and ICT (NRF-2018R1C1B5085214)).